NKCL Bio Group Inc. Business Summary
Experience
•
Hospital MSO Operation Experience: Extensive experience in managing Medical Service Organizations (MSO).
•
Abundant Clinical Know-How: Rich clinical expertise and knowledge gained from numerous hospital operations.
Technology
•
NK Cell Culture Patents: Holder of original patents for NK cell culture, with 14 patents registered (including 4 overseas) and 17 patents pending (including 9 overseas). Additionally, there are 2 exclusive licenses.
•
Expert Groups: Teams of NK cell culture experts and clinical and licensing specialists.
Pipeline
•
Pre-Clinical Stage Completion: The RK-NKTM pre-clinical stage was completed in 2022. The pipeline targets major cancers including liver cancer, breast cancer, kidney cancer, and lung cancer.
Bio Systems
•
NK Cell Automatic Culture System: Developed an automatic culture system for NK cells and completed the Automatic Culture Center.
•
AI Technology Integration: Differentiation through the integration of AI technology.
•
Anti-Cancer Immune Cell Therapy R&D: Established robust infrastructure for the research and development of anti-cancer immune cell therapies.
NKCL Bio Group Inc. leverages its abundant clinical experience and original technology to develop automatic culture technology and a robust biopharmaceutical pipeline, positioning itself as a leader in the field of anti-cancer immune cell therapy.